{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:50:49Z","timestamp":1788691849660,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Viruses"],"abstract":"<jats:p>Cell culture rabies vaccines were initially licensed in the 1980s and are essential in the prevention of human rabies. The first post-exposure prophylaxis (PEP) vaccination regimen recommended by the World Health Organization (WHO) was administered intramuscularly over a lengthy three-month period. In efforts to reduce the cost of PEP without impinging on safety, additional research on two strategies was encouraged by the WHO including the development of less expensive production methods for CCVs and the administration of reduced volumes of CCVs via the intradermal (ID) route. Numerous clinical trials have provided sufficient data to support a reduction in the number of doses, a shorter timeline required for PEP, and the approval of the intradermal route of administration for PEP and pre-exposure prophylaxis (PreP). However, the plethora of data that have been published since the development of CCVs can be overwhelming for public health officials wishing to review and make a decision as to the most appropriate PEP and PreP regimen for their region. In this review, we examine three critical benchmarks that can serve as guidance for health officials when reviewing data to implement new PEP and PreP regimens for their region including: evidence of immunogenicity after vaccination; proof of efficacy against development of disease; and confirmation that the regimen being considered elicits a rapid anamnestic response after booster vaccination.<\/jats:p>","DOI":"10.3390\/v13071252","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T23:57:22Z","timestamp":1624838242000},"page":"1252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Route of Administration of Rabies Vaccines: Comparing the Data"],"prefix":"10.3390","volume":"13","author":[{"given":"Deborah J.","family":"Briggs","sequence":"first","affiliation":[{"name":"Department of Diagnostic Medicine\/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Medicine\/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"World Health Organization (2018). Rabies Vaccines: WHO Position Paper\u2014April 2018. Wkly. Epidemiol. Rec., 93, 201\u2013220.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.20506\/rst.37.2.2824","article-title":"Proof of concept of mass dog vaccination for thecontrol and elimination of canine rabies","volume":"37","author":"Cleaveland","year":"2018","journal-title":"Rev. Sci. Tech."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"A77","DOI":"10.1016\/j.vaccine.2019.01.015","article-title":"Priorities in applied research to ensure programmatic success in the global elimination of canine rabies","volume":"37","author":"Rupprecht","year":"2019","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.03.023","article-title":"Successful strategies implemented towards the elimination of canine rabies in the Western Hemisphere","volume":"143","author":"Escobar","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/epirev\/mxz014","article-title":"Postexposure Effects of Vaccines on Infectious Diseases","volume":"41","author":"Gallagher","year":"2019","journal-title":"Epidemiol Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1001\/jama.1976.03270250019017","article-title":"Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum","volume":"236","author":"Bahmanyar","year":"1976","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.aje.a112207","article-title":"Immunization schedules for the new human diploid cell vaccine against rabies","volume":"103","author":"Plotkin","year":"1976","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1586\/14760584.2016.1140040","article-title":"Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention","volume":"15","author":"Rupprecht","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_9","unstructured":"World Health Organization (2021, May 25). Preualification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Available online: https:\/\/extranet.who.int\/pqweb\/vaccines\/list-prequalified-vaccines."},{"key":"ref_10","first-page":"693","article-title":"Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine","volume":"78","author":"Briggs","year":"2000","journal-title":"Bull. World Health Organ."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/hv.2.5.3197","article-title":"Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML","volume":"2","author":"Madhusudana","year":"2006","journal-title":"Hum. Vaccin"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/clinids\/20.3.646","article-title":"Immunogenicity of purified duck embryo rabies vaccine (Lyssavac-N) with use of the WHO-approved intradermal postexposure regimen","volume":"20","author":"Khawplod","year":"1995","journal-title":"Clin. Infect. Dis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2016.08.005","article-title":"A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes","volume":"34","author":"Bose","year":"2016","journal-title":"Vaccine"},{"key":"ref_14","first-page":"361","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 4","volume":"36","author":"Atanasiu","year":"1967","journal-title":"Bull. World Health Organ."},{"key":"ref_15","first-page":"48","article-title":"Rabies immune globulin (human) in the prevention of rabies","volume":"33","author":"Cabasso","year":"1976","journal-title":"Am. J. Hosp. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"World Health Organization (2018). Rabies vaccines: WHO position paper, April 2018\u2014Recommendations. Vaccine, 36, 5500\u20135503.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0092-1157(75)90061-X","article-title":"Measurement of rabies antibody: Comparison of the mouse neutralization test (MNT) with the rapid fluorescent focus inhibition test (RFFIT)","volume":"3","author":"Louie","year":"1975","journal-title":"J. Biol. Stand."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0092-1157(79)80038-4","article-title":"A collaborative study on the testing of rabies immune globulin (human) by the mouse neutralization test (MNT) and the rapid fluorescent focus inhibition test (RFFIT)","volume":"7","author":"Fitzgerald","year":"1979","journal-title":"J. Biol Stand."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1439-0450.2000.00362.x","article-title":"The modification of fluorescent antibody virus neutralization (FAVN) test for the detection of antibodies to rabies virus","volume":"47","author":"Hostnik","year":"2000","journal-title":"J. Vet. Med. B Infect. Dis. Vet. Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fang, Y., Chen, L., Liu, M.Q., Zhu, Z.G., Zhu, Z.R., and Hu, Q. (2014). Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: A study based on different age groups. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003412"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.4161\/hv.29403","article-title":"Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis","volume":"10","author":"Ravish","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4161\/hv.26456","article-title":"Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India","volume":"10","author":"Madhusudana","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_25","unstructured":"World Health Organization (2017). WHO Immunization Basis for Immunization Series: Module 17 Rabies Update 2017, World Health Organization."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.vaccine.2021.01.023","article-title":"Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis","volume":"39","author":"Xu","year":"2021","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/infdis\/jiz645","article-title":"Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis","volume":"221","author":"Endy","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210C","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: A systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(85)92367-0","article-title":"Economical multiple-site intradermal immunisation with human diploid-cellstrain vaccine is effective for post-exposure rabies prophylaxis","volume":"1","author":"Warrell","year":"1985","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0140-6736(90)90488-Q","article-title":"Postexposure prophylaxis for rabies with antiserum and intradermal vaccination","volume":"335","author":"Chutivongse","year":"1990","journal-title":"Lancet"},{"key":"ref_31","first-page":"33","article-title":"Humoral and Cell-mediated Immune Responses to Various Economical Regimens of Purified Vero Cell Rabies Vaccine","volume":"5","author":"Phanuphak","year":"1987","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14760584.2018.1473765","article-title":"Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: A systematic literature review and meta-analysis","volume":"17","author":"Preiss","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2009.09.090","article-title":"A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab)","volume":"28","author":"Ashwathnarayana","year":"2009","journal-title":"Vaccine"},{"key":"ref_34","first-page":"491","article-title":"An effective economical intradermal regimen of human diploid cell rabies vaccination for post-exposure treatment","volume":"63","author":"Ubol","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Moulenat, T., Petit, C., Bosch Castells, V., and Houillon, G. (2020). Purified Vero Cell Rabies Vaccine (PVRV, Verorab((R))): A Systematic Review of Intradermal Use Between 1985 and 2019. Trop. Med. Infect. Dis., 5.","DOI":"10.3390\/tropicalmed5010040"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1016\/j.vaccine.2006.02.036","article-title":"Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): An immunogenic, cost-effective and practical regimen","volume":"24","author":"Ambrozaitis","year":"2006","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0264-410X(00)00342-X","article-title":"Purified Chick Embryo Cell Culture Rabies Vaccine: Interchangeability with Human Diploid Cell Culture Rabies Vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons","volume":"19","author":"Briggs","year":"2000","journal-title":"Vaccine"},{"key":"ref_38","first-page":"192","article-title":"Boosting effect of purified chick embryo cell rabies vaccine using the intradermal route in persons previously immunized by the intramuscular route or vice versa","volume":"19","author":"Sudarshan","year":"2006","journal-title":"Natl. Med. J. India"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2008.04.081","article-title":"Intradermal pre-exposure rabies vaccine elicits long lasting immunity","volume":"26","author":"Brown","year":"2008","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/cid\/ciy513","article-title":"Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days","volume":"68","author":"Soentjens","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"De Pijper, C.A., Langedijk, A.C., Terryn, S., Van Gucht, S., Grobusch, M.P., Goorhuis, A., and Stijnis, C. (2021). Long-term memory response after a single intramuscular rabies booster vaccination, 10\u201324 years after primary immunization. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiab034"}],"updated-by":[{"DOI":"10.3390\/v14071368","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000}}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:24:09Z","timestamp":1754259849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071252"],"URL":"https:\/\/doi.org\/10.3390\/v13071252","relation":{"correction":[{"id-type":"doi","id":"10.3390\/v14071368","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]}}}